T-CELL ACTIVATION CONTROLLING EFFECTS OF ETHYL ACETATE FRACTION OF KALANCHOE PINNATA (LMK) PERS ON TMPD-TREATED LUPUS MICE
AbstractT-cell activation, with the low expression of CD62L (L-selectin) marker in the spleen, will increase B cell activity to produce lupus antibodies. Therefore, lupus patients need drugs which could increase the L- selectin expression in the spleen to reduce the auto-reactive T cell. The tested drug to increase the L-selectin in this research was the ethyl acetate fraction of Kalanchoe pinnata (Lmk) Pers leaves (EF-KP), based on its immunosuppressant and anti-inflammatory activities. The research was performed by means of 2, 6, 10, 14 tetramethylpentadecane (TMPD) induced lupus-like mice. The experimental groups consisted of negative control (NC), EF-KP, and positive control (PC) groups. After 21 day treatment, the blood leukocyte was checked. Then, the spleen was prepared for the flow cytometry method to measure CD4+CD62L+ and CD8+CD62L+ T cells. The relative percentage of CD4+CD62L+ T cells in EF-KP groups increased insignificantly (p>0.05) (NC=7.91 ± 4.98%, EF-KP = 8.63 ± 3.07%, PC = 12.62 ± 8.09%). The relative percentage of CD8+CD62L+ T cells increased significantly (p < 0.05) (NC = 6.20 ± 4.91%, EF-KP = 15.94 ± 9.37%, PC = 24.32 ± 17.47%). Additionally, the total leukocytes reduced significantly (p < 0.05) (NC = 6.333 ± 1.078 cells/mm3, EF-KP = 4.967 ± 635 cells/mm3, PC = 4.367 ± 1.102 cells/mm3). The results show that the active compounds in the EF-KP can mainly control the L-selectin regulatory function of CD8+ T cells, and then reduce the inflammation process with the point view of reducing its total leukocytes. At last, the main compounds in the EF-KP could control the T-cell activation in lupus.
Article Information
7
475-482
542
1404
English
IJPSR
N. Indriyanti, J. Soeroso and J. Khotib*
Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga, Jl. Dharmawangsa Surabaya, Indonesia.
junaidi-k@ff.unair.ac.id
17 May, 2017
17 July, 2017
25 July, 2017
10.13040/IJPSR.0975-8232.9(2).475-82
01 February, 2018